INVERSAGO PHARMA
A specialized, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome (PWS), Type-1 Diabetes (T1D), obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH). Inversago’s technology addresses limits associated with first generation CB1 blockers, allowing the company to exploit their full medical potential.
INVERSAGO PHARMA
Social Links:
Industry:
Biopharma Biotechnology Health Care Medical Pharmaceutical
Founded:
2015-01-01
Address:
Montréal, Quebec, Canada
Country:
Canada
Website Url:
http://www.inversago.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
42 M USD
Similar Organizations
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Calimmune
Calimmune is a clinical-stage gene therapy company.
Continuous Precision Medicine
Continuous Precision Medicineâ„¢ is a leader in the fight against the opioid epidemic.
Giiant Pharma
Giiant Pharma is a preclinical-stage biotech company.
Hangzhou Just Biotherapeutics (Just China)
Hangzhou Just Biotherapeutics is a comprehensive high-tech design company.
Metera Pharmaceuticals
Metera Pharmaceuticals is a preclinical stage biotechnology company.
Neuraly
Neuraly is a startup biotech company.
Portal Instruments
Portal Instruments is an early stage company that offers medical device.
Scarless Laboratories
Scarless Laboratories is a Beverly Hills-based research-focused early-stage biotechnology company.
ZSX Medical
ZSX Medical, LLC, is a pre-clinical stage medical device company.
Current Advisors List
Current Employees Featured
Founder
Investors List
AQC Capital
AQC Capital investment in Series B - Inversago Pharma
Fonds de solidarité FTQ
Fonds de solidarité FTQ investment in Series B - Inversago Pharma
Amorchem
Amorchem investment in Series B - Inversago Pharma
JDRF T1D Fund
JDRF T1D Fund investment in Series B - Inversago Pharma
adMare Bio Innovations
adMare Bio Innovations investment in Series B - Inversago Pharma
Genesys Capital
Genesys Capital investment in Series B - Inversago Pharma
Forbion Capital Partners
Forbion Capital Partners investment in Series B - Inversago Pharma
AQC Capital
AQC Capital investment in Series A - Inversago Pharma
JDRF T1D Fund
JDRF T1D Fund investment in Series A - Inversago Pharma
Anges Quebec
Anges Quebec investment in Series A - Inversago Pharma
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-17 | Inversago Pharma Appoints Glenn S. Vraniak as Chief Financial Officer |
Official Site Inspections
http://www.inversago.com
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Inversago Pharma"
Inversago Pharma – The peripheral CB1 blockade …
Inversago Pharma is a preclinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.See details»
Inversago Pharma - Crunchbase Company Profile
Inversago Pharma is a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonistsSee details»
Inversago Pharma - Overview, News & Similar companies
View Inversago Pharma (www.inversago.com) location in Quebec, Canada , revenue, industry and description. Find related and similar companies as well as employees by title and much …See details»
Inversago Pharma - LinkedIn
Inversago Pharma | 2,630 followers on LinkedIn. Pioneer in the development of peripheral CB1 inverse agonists | Located in Montreal, Inversago Pharma is a privately-owned Canadian …See details»
Inversago Pharma - 2025 Company Profile & Team
Jul 21, 2025 Explore Inversago Pharma's in-depth company profile, including funding details, key investors, and leadership.See details»
Contact us – Inversago Pharma
INVERSAGO A Novo Nordisk company 1100 René-Lévesque Blvd West Suite 1110 Montreal, Quebec H3B 4N4 Canada 1 438 300-2534See details»
Inversago Pharma Inc. - life-sciences-europe.com
Based in Montreal Canada, Inversago Pharma, is a privately owned, clinical stage company, and leader in the development of next generation CB1 receptor blocker therapies designed to help …See details»
Inversago Pharma: Contact Details and Business Profile
Inversago Pharma is a Pharmaceuticals, Biotechnology Research, and Drug Manufacturing & Research company_reader located in Montreal, Quebec with $405000 in revenue and 22 …See details»
Inversago Pharma Company Profile - Office Locations ... - Craft
Inversago Pharma has 5 employees at their 1 location and $42 m in total funding,. See insights on Inversago Pharma including office locations, competitors, revenue, financials, executives, …See details»
Inversago Pharma - Executive Bio, Top Executies, and Transitions ...
View the organization profile of Inversago Pharma,Corporate and financial executive with more than thirty years of experience in finance and administration roles with increasing …See details»
Inversago Pharma Inc Company Profile | Montréal, QC, Canada ...
Find company research, competitor information, contact details & financial data for Inversago Pharma Inc of Montréal, QC. Get the latest business insights from Dun & Bradstreet.See details»
Inversago Pharma - Osler, Hoskin & Harcourt LLP
Inversago Pharma is a Montreal-based, privately owned biotech company at clinical stage, specializing in the development of new therapies focusing on CB1 blockade.See details»
Inversago - VentureRadar
"A specialized, preclinical-stage biotech company, Inversago Pharma develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the …See details»
Novo Nordisk to acquire Inversago Pharma to develop new
Aug 10, 2023 Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases Français News provided by …See details»
Novo Nordisk acquires Inversago Pharma - 2023-08-10
Aug 10, 2023 Overview Acquired Organization: Inversago Pharma Inversago Pharma is a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonistsSee details»
Inversago Pharma Company Overview, Contact Details
Dec 12, 2020 Learn more about Inversago Pharma's company details, contact information, competitors, and more. Find accurate contact data easily with LeadIQ. Book a demo today.See details»
Inversago Pharma - Profiles & Contacts - Crunchbase
Inversago Pharma is a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonistsSee details»
Novo Nordisk to acquire Inversago Pharma to develop new …
The acquisition of Inversago includes the company’s lead development asset INV-202, an oral CB1 inverse agonist. INV-202 is designed to preferentially block the receptor protein CB1 – …See details»
Inversago Pharma - osler.com
Inversago is a specialized, preclinical-stage biotech company that develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the …See details»
Inversago Pharma Careers, Perks + Culture | Built In
Learn more about Inversago Pharma. Find jobs, explore benefits, and research company culture at Built In.See details»